Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | TIPARP | Q7Z3E1 | 3/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233803 | 1.00 | SCN9A (0.44) | SCN9ASCN10APRKCQCHRM4GPR119 | |
| SCHEMBL28966676 | 0.86 | HTT (0.43) | SCN9APRKCQCHRM4SLC6A9TIPARP | |
| SCHEMBL28966665 | 0.86 | HTT (0.43) | SCN9APRKCQCHRM4SLC6A9TIPARP | |
| SCHEMBL28966662 | 0.86 | HTT (0.43) | SCN9APRKCQCHRM4SLC6A9TIPARP | |
| SCHEMBL83060 | 0.84 | PRKCQ (0.41) | SCN9ASCN10APRKCQGPR119ADRB1 | |
| SCHEMBL24963024 | 0.84 | SCN9A (0.42) | SCN9ACHRM4ADRB1SLC6A9TIPARP | |
| SCHEMBL19035707 | 0.81 | PRKCQ (0.49) | PRKCQADRB1 | |
| SCHEMBL27233830 | 0.80 | CHRM4 (0.36) | CHRM4SLC6A9TIPARPACACB | |
| SCHEMBL27233825 | 0.80 | CHRM4 (0.36) | CHRM4SLC6A9TIPARPACACB | |
| SCHEMBL12356311 | 0.80 | HTR2C (0.42) | SCN9ACHRM4SLC6A9ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | SCN9A 3361/4885SCN10A 3115/4885PRKCQ 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.